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ABSTRACT
MicroRNAs (miRNAs) are essential small RNA mol-
ecules (20–24 nt) that negatively regulate the ex-
pression of target genes at the post-transcriptional 
level. Due to their roles in a variety of biological pro-
cesses, the aberrant expression profiles of miRNAs 
have been identified as biomarkers for many dis-
eases, such as cancer, diabetes, cardiovascular dis-
ease and neurodegenerative diseases. In order to 
precisely, rapidly and economically monitor the ex-
pression of miRNAs, many cutting-edge nanotech-
nologies have been developed. One of the nano-
technologies, based on DNA encapsulated silver 
nanoclusters (DNA/AgNCs), has increasingly been 
adopted to create nanoscale bio-sensing systems 
due to its attractive optical properties, such as 
brightness, tuneable emission wavelengths and 
photostability. Using the DNA/AgNCs sensor meth-
ods, the presence of miRNAs can be detected sim-
ply by monitoring the fluorescence alteration of 
DNA/AgNCs sensors. We introduce these DNA/
AgNCs sensor methods and discuss their possible 
applications for detecting miRNA biomarkers in 
neurodegenerative diseases.
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INTRODUCTION
As the fundamental unit of living organisms, the 
cell runs thousands of biochemical reactions with 
high accuracy, precision and efficiency. The systemic 
regulation of cellular processes involves a variety of 
regulatory components and pathways. To study these 
sophisticated systems, researchers rely on cellular 
biomarkers as the representatives of any given cellu-
lar reaction. The biomarkers provide key informa-
tion about the normal biological processes, as well as 
the pathogenic or disease conditions that arise in re-
sponse to external signals or internal imbalances. 
One highly attractive class of biomarkers comprises 
the nucleic acids (NAs), i.e., DNA and RNA, because 
of their easy extraction from non-invasive samples 
such as blood, urine and stool for prognosis and di-
agnosis.1,2 One of the most widely used biomarkers, 
with a huge potential for practical applications, is a 
class of small RNA molecules known as microRNAs 
(miRNAs).3 miRNAs are short non-coding RNAs 
that are 21−22 nucleotides in length and are involved 
in the regulation of gene expression at the post-tran-
scriptional level.4 Detailed studies have revealed the 
spatial and temporal occurrence of many miRNAs, 
as well as their unique biological roles in messenger 
RNA (mRNA) cleavage and translational suppres-
sion. More than 2000 miRNAs have been identified 
in humans, and many of them are functionally in-
volved in diseases, showing great potential as bio-
markers.4-6 However, for the practical applications of 
miRNAs as biomarkers, highly reliable, economic, 
and convenient detection methods are required in 
addition to the currently available methods. Thus, 
there has been a surge in the interest of developing 
improved miRNA detection methods, especially us-
ing nanotechnological tools.5-9 One such advanced 
tool that has drawn particular attention is the use of 
the fluorescent properties of silver nanoclusters 
(AgNCs).10-12 When clustered silver atoms approach 
a size less than 2 nm, due to quantum confinement, 
AgNCs exhibit unique properties such as strong and 
stable fluorescence.12,13 The synthesis of AgNCs in 
aqueous solutions, using stabilizing scaffolds such as 
NAs, has allowed for a large number of applications 
for the detection of biomolecules.14-16 The funda-
mental understanding of the role and properties of 
NAs, as well as their influence on the fluorescent syn-
thesis of AgNCs, has increased in recent years.17-21 By 
exploiting such new technology, research groups 
have developed several reliable methods for NA/
AgNCs-based miRNA detection.10,22 In this review, 
we discuss the current findings of miRNAs as bio-
markers for human diseases, especially neurodegen-
erative diseases, and how miRNAs can be efficiently 
determined, with an emphasis on novel nanosensor 
methods.
BIOLOGY OF MICRORNAS
The biological impacts of the small RNA mole-
cules remained unnoticed until the last part of the 
20th century, but the discovery of miRNA by the 
group of Victor Ambros opened up a whole new av-
enue of research.4 The miRNAs turned out to be very 
important regulators of gene expression.4 Recent 
studies on their origin, biogenesis and mechanisms 
of action have greatly advanced our knowledge of 
the molecular biology of miRNAs.4 miRNAs are 
generated through two step-wise processes involving 
the coordinated functions of a multi-protein com-
plex known as the microprocessor.23-25 Primary miR-
NAs are transcribed from MIRNA genes and then 
processed into precursor miRNAs and further to 
mature miRNAs by the microprocessor.23 Mature 
miRNAs are then loaded onto the so-called RNA-In-
duced Silencing Complex to recognize target mRNAs 
through sequence complementarity. The complex of 
the protein machinery with a loaded miRNA can ei-
ther remove target mRNA or repress the translation 
of mRNA.26,27 The levels of miRNAs are often differ-
entially modulated by the growth and developmental 
stage of organisms, specific cell and tissue types, and 
environmental stimuli.3,28-33
MIRNA BIOMARKERS IN HUMAN 
NEURODEGENERATIVE DISEASES
Many studies have suggested that miRNAs can be 
important biomarkers in a variety of diseases, in-
cluding cancer, diabetes, cardiovascular disease, ag-
ing, asthma, autoimmune disease, kidney diseases, 
and neurodegenerative diseases.3,34-46 Due to the po-
tential of miRNA as biomarkers, several studies have 
predicted that monitoring methods for miRNAs will 
be extensively useful for curing those diseases in the 
near future.42,47-50 Among the defined miRNAs, we 
focused our discussion on miRNAs associated with 
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neurodegenerative diseases in this review. Neurode-
generative disorders−Alzheimer’s disease (AD), Hun-
tington’s disease (HD), Parkinson’s disease (PD), amy-
otrophic lateral sclerosis (ALS), and prion diseases−
are defined by the progressive loss of specific neuronal 
cells in the central nervous system. These diseases 
commonly cause significant defects in motor and 
cognitive ability. Recently, a number of studies have 
revealed that specific miRNAs are differentially ex-
pressed in the human brain and, more importantly, 
some of the miRNAs modulate genes associated 
with specific neurodegenerative disorders. For in-
stance, Harraz et al.51 showed that among 224 miR-
NAs sequenced, miR-133b, miR218-2, miR-15b, 
miR101-1, miR107, miR-335, and miR-345 were no-
tably down-regulated in PD patients. miR-133b seems 
to be functional as a negative regulator of Pitx3, an 
important transcriptional factor that is involved in 
the differentiation of dopaminergic neurons.52-54 In-
terestingly, miR-133 and Pitx3 modulate the expres-
sion of each other through a negative feedback regula-
tion. Pitx3 induces MIR-133 gene expression, which 
in turn targets Pitx3 to be degraded.55 The profiling 
of miRNAs in PD brains uncovered decreased ex-
pression of miR-34b and miR-34c in the affected 
brain areas.56 The reduction of miR-34b/34c inverse-
ly enhanced the expression of α-synuclein in human 
dopaminergic SH-SY5Y cells.57 The sequence varia-
tions in the miR-433 recognition site of fibroblast 
growth factor 20 (FGF20) may disrupt the miR-
433-mediated silencing of FGF20, and that results in 
the increased expression of α-synuclein, which con-
fers risk for PD.58 Three differentially regulated miR-
NAs−miR-1, miR-22*, and miR-29−were identified 
in the blood samples of PD patients compared to 
healthy subjects, showing the feasibility of miRNAs 
as biomarkers.59
β-amyloid cleavage enzyme 1 (BACE-1) is required 
for the cleavage of amyloid precursor protein (APP), 
which thereby generates toxic Aβ species.60 The ex-
pression of BACE-1/β-secretase is inversely correlated 
with the levels of miRNAs from the miR-29a/b-1 
family, showing that BACE-1/β-secretase is a target of 
this family miRNA.61 Interestingly, in a group of AD 
patents, the expression of miR-29a/b-1 clusters was 
significantly down-regulated.61,62 Two additional 
miRNAs, miR-298 and miR-328, also seem to play 
essential roles in down-regulating BACE-1/β-secretase 
expression.61,63 The level of miR-107 is reduced in the 
brains of AD patients and that is inversely correlated 
with the increased levels of BACE-1/β-secretase and 
cofilin, showing the role of miR-107 in human AD.64,65 
Cyclin-dependent kinase 5, a tau kinase which is dys-
regulated in AD, and the metalloproteinase ADAM10, 
which is important for APP processing, are also tar-
geted by miR-107.66 miR-15 targets a pathological 
hallmark gene of AD, extracellular signal-regulated 
kinase 1, a tau kinase. The level of miR-15 is also de-
creased in AD patiens.67 Other studies have demon-
strated that the miR-29 family seems to play a role in 
the modulation of microglial activity. The miR-29 
family also targets the microglial modulators insulin-
like growth factor-1 (IGF-1) and fractalkine ligand 
(CX3CL1). Indeed, the increased level of miR-29b 
was inversely correlated with the expression of IGF-1 
and CX3CL1 in human cortical tissue, implying the 
role of the miR-29 family in brain aging.68 p53 is 
highly upregulated in AD and induces tau hyper-
phosphorylation. The miR-34 family is transcrip-
tionally induced by p53 and is also considered a criti-
cal mediator of p53 functions. Accordingly, miR-34 is 
found at high levels in the hippocampus of AD pa-
tients, and the down-regulation of miR-34 rescues 
some cognitive defects.69,70 miR-106a and miR-106b 
are complementary to the transcript of APP, which is 
increased in AD patients. Consistently, these miR-
NAs are reduced in the temporal lobe of AD pa-
tients. The expression of the transporter ABCA1 is 
also regulated by miR-106a and miR-106b, confirm-
ing the roles of the miR-106 family in AD process-
es.71 An miRNA dysfunction in AD could be a cause, 
but in some cases, it could also be a result of AD 
progress. For example, miR-181c is down-regulated 
by Aβ in in vitro hippocampal cultures. This reduc-
tion of miR-181c is recapitulated in Aβ-depositing 
APP23 transgenic mice and in human AD tissue.72 
In contrast, miR-9, miR-125b, and miR-128 are in-
creased in the hippocampal region of AD-affected 
brains.73 In the case of miR-146a, it is upregulated in 
the temporal cortex of AD patients, and complement 
factor H is a target of miR-146a, indicating that miR-
146a mediates AD-related inflammation.74 Other 
miRNAs have been associated with AD, such as miR-
124, miR-132, and miR-153. Most of them seem to 
be implicated in APP processing, neuro-inflamma-
tion, tau hyper-phosphorylation, and ApoE-lipidi-
zation.66,75
The pathogenic poly-glutamine expanded hun-
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tingtin (HTT) causes HD, a hereditary neurodegen-
erative disorder. In normal neurons, HTT forms a 
complex with repressor element 1 silencing transcrip-
tion factor (REST) in the cytoplasm, which sup-
presses the translocation of REST into the nucleus. 
The REST-HTT interaction can be abolished by the 
pathogenic modification of HTT, which consequent-
ly leads to neuronal death.76,77 The transcript of REST 
is targeted by miR-9; therefore, the reduction of miR-
9 in HD brains could cause the accumulation of free 
REST protein. Indeed, the cerebral cortex of HD 
brains have considerably reduced levels of miR-9, 
showing the importance of miR-9 in HD.78 miR-132 
is notably down-regulated in the post-mortem 
brains of HD patients. The reduction of miR-132 is 
known to increase its target, p250GAP, encoding a 
member of the group of GTPase-activating proteins, 
which inhibit neurite outgrowth, resulting in HD 
progress.79,80
Although we have hitherto discussed miRNAs 
dysregulation in AD, PD, and HD, there are many 
miRNAs that are directly or indirectly involved in 
other neurological disabilities (Table 1), such as epi-
lepsy, ALS, traumatic brain injury, and prion diseas-
es. Recent studies have shed light on the impacts of 
numerous miRNAs on the pathogenesis and pro-
gression of neurodegenerative diseases. However, 
comprehensive profiles of the effects of different sets 
of miRNAs that are related to a specific disease still 
remain elusive. Not only for disease diagnosis but 
also for prognosis, the expression profile of miRNAs 
must be precisely and efficiently characterized. To 
meet the demand, a variety of methods for miRNA 
profiling have been developed, some of which are 
discussed below.
INTRODUCTION TO SILVER 
NANOCLUSTERS
Metal nanoclusters (MNCs) exhibit size-depen-
dent distinct optical properties unlike their bulk coun-
terpart material.12,13,81 When the metal size approach-
es the Fermi wavelength, the continuous density of 
states becomes discrete and all the electronic wave-
functions are overlapped.82 In this size regime, 
MNCs may behave as molecular systems, where en-
ergy levels are separated to allow direct electronic 
transitions due to quantum confinement (Figure 1). 
Because of their behavior as “pseudo-atoms,” the met-
al clusters exhibit unique properties such as strong 
photoluminescence.83,84 Among MNCs, AgNCs have 
gained more prominence due to their brighter fluo-
rescence emission. AgNCs are unstable in solution, 
and they readily aggregate to form large particles or 
aggregates lacking any fluorescence properties. For 
biological application purposes, a water soluble and 
biocompatible encapsulating ligand is required to re-
strict the growth of AgNCs in the specific size regime 
(< 2 nm).11,12 In recent years, many studies have shown 
the development of AgNCs using different stabiliz-
ing templates, such as dendrimers, peptides, and thi-
olates.81,85-88 Among the various stabilizing templates 
Table 1. List of miRNAs which are related to neurodegenerative diseases
Neurodegenerative diseases Expression Profiled miRNAs
AD
Increased miR-146a, miR-197, miR-320, miR-423, miR-511
Decreased
let-7i, miR-9, miR-15a, miR-22, miR-26b, miR-29a.b-1, miR-30a-5p, miR-93, 
miR-98, miR101, miR-106b, miR-107, miR-181c, miR-210, miR-363 
PD
Increased miR-1, miR-22
Decreased
miR-7, miR-15b, miR-16-2*, miR-19b, miR-26a/a2*, miR-28-5p, miR-29, miR-29b/c, 
miR-30a/b/c, miR-34b/c, miR-101-1, miR-107, miR-126, miR-126*, miR-133b, miR-147, 
miR-151-5p, miR-133, miR-199a-3p, miR-199a-5p, miR-218-2, miR-301a, miR-335, 
miR-345, miR-374a/b 
HD
Increased
miR-29a, miR-330, miR-132, miR-196, miR-486, miR-100, miR-151-3p, 
miR-16, miR-219-2-3p, miR-27b, miR-451, miR-92a, miR-34b
Decreased
miR-9/9*, miR-22, miR-29c, miR-124a, miR-128, miR-138, miR-132, miR-128, 
miR-222, miR-344, miR-674*
ALS
Increased
miR-338-3p, miR-27a, miR-155, miR-146a, miR-32-3p
miR-146*, miR-524-5p miR-582-3p, miR-24-2*, miR-142-3p, miR-142-5p, miR-1461, miR-146b
Decreased miR-451, miR-1275, miR-328, miR-638, miR-149, miR-665, miR-583
miRNAs: microRNAs, AD: Alzheimer’s disease, PD: Parkinson’s disease, HD: Huntington’s disease, ALS: amyotrophic lateral sclerosis.
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for emissive AgNCs formation, we here focus on a 
type of biocompatible template, NAs, for generating 
AgNCs. Due to the biological implications of DNA 
and RNA, NAs have attracted great attention as scaf-
fold templates for emissive AgNCs. The first major 
advancement in this direction was achieved by Dick-
son’s group.11 Not only could a strong emission be 
measured from the DNA AgNCs, but as shown by 
Dickson’s group, the emission wavelength of the 
AgNCs could also be altered (Figure 2).89,90 Further-
more, the structure and sequences of NAs can create 
an excellent interface between the fluorescent prop-
erties of AgNCs and biological applications. There-
fore, a whole new avenue of applications was opened 
with the findings from Dickson’s group, proving the 
potential of NAs as a stabilizing template for AgNCs.11 
In subsequent studies, many research groups focused 
on understanding the fundamental mechanisms un-
derlying the utility of AgNCs as fluorophores. Al-
though these studies suggested many interesting 
findings on the nature of AgNCs that are worthwhile 
to discuss in detail, we here focus on discussing the 
applications of DNA/AgNCs sensors for miRNAs.
DNA/AGNCS-BASED METHODS 
FOR MIRNA DETECTION
For the first time, Petty et al.91 demonstrated the 
potential value of DNA/AgNCs for the detection of 
DNA, where a bi-functional DNA sensor was used. 
One component of the sensor was composed of a 
Figure 1. Size-dependent properties of different metallic states. Modified from 
Pettibone et al. ACS Nano 2013;7:2491-2499, with permission of American 
Chemical Society.13
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Figure 2. Tuning of the oligonucleotide base sequence in a 12-mer DNA, resulted in generating AgNCs emitters with different fluorescence 
values. Steady-state excitation and emission spectra for five distinct ss-DNA-encapsulated Ag nanoclusters. A: Blue emitters created in 
5′-CCCTTTAACCCC-3′. B: Green emitters created in 5′-CCCTCTTAACCC-3′. C: Yellow emitters created in 5′-CCCTTAATCCCC-3′. D: Red 
emitters created in 5′-CCTCCTTCCTCC-3′. E: Near IR emitters created in 5′-CCCTAACTCCCC-3′. F: Pictures of emissive solutions in A-D. 
Adapted from Richards et al. J Am Chem Soc 2008;130:5038-5039, with permission of  American Chemical Society.90 AgNCs: silver nano-
clusters.
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cytosine-rich sequence, and the other part was a se-
quence complementary to the target DNA sequenc-
es. The presence of the target DNA sequence en-
hanced the fluorescence of the DNA/AgNCs sensor 
approximately 2−3-fold, enabling the sensor to be 
used in a turn-on method for detecting a specific 
DNA fragment. In a further development of the sys-
tem, the same group showed that the wavelength 
shift, rather than altered fluorescence intensity, can 
be used to detect a target DNA fragment.91  By apply-
ing the potential of DNA/AgNCs-based methods, 
Yang and Vosch10 reported for the first time a DNA/
AgNCs-based method for miRNA detection. A 
DNA-sensor consists of two components, a cytosine-
rich scaffold and a DNA sequence complementary 
to the target miRNA. The DNA sensor generates a 
bright red fluorescence within 1 hour and drops the 
fluorescence in the presence of target miRNA. This 
“turn-off”-based method allows the quantitative de-
tection of miRNA down to a picomole level (Figure 
3). Because of the huge diversity of miRNA sequenc-
es in Arabidopsis and humans, Shah et al.20 attempt-
ed to systemically design DNA/AgNCs sensors by 
changing only the target miRNA sensing sequences. 
However, they found that the systemic designing of 
DNA/AgNCs sensors was not simply established by 
replacing the target sensing sequences for each miR-
NA. Through detailed analysis, they suggested that 
the secondary structure of DNA/AgNCs sensors, in-
cluding the silver encapsulating C-rich scaffold, is 
essential for the generation of fluorescence and target 
recognition.20 Based on this finding, they reconsti-
tuted the C-rich scaffold and target recognition se-
quences of the non-functional DNA/AgNCs sensor 
(for miR172 in plants) to be structured, and that was 
eventually functional in detecting target miRNA. 
Next, Shah et al.92 demonstrated that RNA and a 
DNA/RNA chimera can be an efficient sensor for a 
specific group of human miRNAs because of the ro-
tational freedom of RNA backbones. By introducing 
RNA backbones, they further showed that non-
functional DNA/AgNCs sensors (for let-7a and miR-
200 in humans) can be successfully converted into 
functional RNA/DNA-chimera/AgNCs sensors.93 
The newly developed chimera sensors were highly 
sensitive to recognize let-7a and miR-200 in human 
Figure 3. Fluorescence intensity of the AgNCs formed in 12 nt-RED-160 probe with RNA-miR160 target in a concentration ranging from 0 
to 1.5 μM. The fluorescence spectra were recorded, exciting at 560 nm. Emission spectra (excited at 560 nm) of AgNCs emission from a 
solution containing 1.5 μM of DNA-12 nt-RED-160 probe and 20 μg of endogenous RNA from WT (black curve) or hyl1-2 mutant Arabidop-
sis thaliana plants. Northern blot analysis shows the presence and absence of RNA miR160 in WT and hyl1-2 mutant plants. A: Fluores-
cence intensity of the AgNCs formed in 12 nt-RED-160 probe with RNA-miR160 target in a concentration ranging from 0 to 1.5 μM. The flu-
orescence spectra were recorded, exciting at 560 nm. B: Emission spectra (excited at 560 nm) of AgNCs emission from a solution 
containing 1.5 μM of DNA-12 nt-RED-160 probe and 20 μg of endogenous RNA from WT (black curve) or hyl1-2 mutant Arabidopsis thali-
ana plants. C: Northern blot analysis shows the presence and absence of RNA miR160 in WT and hyl1-2 mutant plants, respectively. 
Adapted from Yang et al. Anal Chem 2011;83:6935-6939, with permission of American Chemical Society.10 AgNCs: silver nanoclusters, WT: 
wild-type.
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cell lines. Furthermore, to improve the designing 
system for DNA/AgNCs sensors, Shah et al.94 sug-
gested a locking-to-unlocking system by which several 
DNA/AgNCs sensors were successfully constructed 
for miR-21, miR-18a, and miR-27b (Figure 4).
These studies also demonstrated the pragmatic 
potential of DNA/AgNCs-based sensors by using bi-
ological samples. For instance, the levels of target 
miR160 in wild-type and in hyl1-2 mutant of Arabi-
dopsis were determined with a DNA/AgNCs sen-
sor.10 Let-7a is now used as a biomarker for many can-
cers in humans, such as colorectal cancer and breast 
cancer. By using chimera/AgNCs sensors, the ex-
pression of let-7a was successfully observed in HT-
29 (a colorectal adenocarcinoma) and MDA-MB-231 
(a breast cancer cell line); miR-200c was monitored 
only in the HT-29 cell line.93 Likewise, miR-21 and 
miR-27b are considered as specific biomarkers of 
cancers such as MCF-7 (a breast cancer cell line) and 
PANC-1 (a non-endocrine pancreatic cancer cell 
line), respectively. The differential expression of miR-
21 and miR-27b in the cell lines was successfully 
monitored by the locking-to-unlocking DNA/
AgNCs methods.94 Yang’s group further applied the 
method to study the processing pathway of miRNA 
in plants and identified that the deficiency of CON-
STITUTIVE PHOTOMORPHOGENETIC 1, a 
negative regulator of photomorphogenesis, led to a 
dramatic reduction of miRNAs.95 The detection of 
miRNA levels by the DNA/AgNCs-based method 
allowed them to rapidly screen out a novel compo-
nent in plant miRNA biogenesis.
In addition to these methods, Zhang et al.96 sug-
gested the use of target-assisted isothermal exponen-
tial amplification coupled with fluorescent DNA/
AgNCs. By using two enzymes, DNA polymerase 
and nicking endonuclease, the polymerization of a 
designed DNA sensor can be initiated upon the bind-
ing of target miRNA. They presented that miR-21 
and miR-141 could be detected with a high specifici-
ty and sensitivity, and claimed that the sensitivity 
was similar to the routinely used quantitative real-
time reverse transcription PCR (qRT-PCR)-based 
method. The outcome of this method was verified 
by qRT-PCR in parallel. Xia et al.97 suggested a new 
type of AgNCs/hairpin DNA sensor where a 5-TCC/
CCC-3’-overhang for embedding emissive AgNCs 
was attached to a target sensing DNA sequence. The 
fluorescence of the sensor was diminished in the 
presence of the target RNA sequence with comple-
mentarity to the sensing DNA sequence. Two hair-
pin DNA-templated AgNCs (AgNCs/HpDNA) sen-
sors were combined with a strand-displacement 
amplification (SDA) procedure to detect miR-16-5p 
and miR-19b-3p, which are known as biomarkers of 
gastric cancer. This method demonstrated that the 
effect of G-rich fluorescence enhancement can be 
successfully implemented in the SDA reaction for 
the rapid and specific detection of miRNAs. Dong et 
al.98 demonstrated that a conformational molecular 
beacon coupled with target recycling amplification 
can be a facile and sensitive miRNA biosensor. In the 
method, the competition displacing between target 
miRNA and Hg2+ provides the biosensor with high 
sequence specificity. Although the functionality of a 
DNA/AgNCs-based method has been proven to 
date with only miRNA biomarkers in cancer cells 
and tissue samples from cancer patients, and because 
some of them are also functional in neurodegenera-
tive diseases, the potential of the method is evidently 
promising for detecting miRNA biomarkers in neu-
rodegenerative diseases.
DISCUSSION
Each of the conventional methods for miRNA de-
tection, such as small RNA blotting, qRT-PCR, and 
Figure 4. Schematic cartoon for the generation of highly emissive AgNCs in 
DNA-RNA chimera sensor. A working model of locking-to-unlocking DNA/
AgNCs sensor in detecting miRNAs. Adapted from Shah et al. Chem Commun 
(Camb) 2014;50:13592-13595, with permission of Royal Society of Chemistry.92 
Adapted from Shah et al. Nucleic Acids Res 2016;44:e57, with permission of 
Oxford University Press.94 AgNCs: silver nanoclusters.
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microarrays, has its own individual drawbacks. For 
instance, small RNA blotting is labor intensive and 
requires radioactive-labeling or very complicated 
DIG-labeling. In general, small RNA blot analysis 
takes at least 2 days to evaluate the levels of miRNAs 
in samples, and its sensitivity is relatively lower than 
other methods. However, this method has a major 
advantage that reflects the actual levels of miRNAs 
in samples, as it reads the signals from direct hybrid-
ization between a probe and target miRNA. qRT-
PCR and microarrays are costly in terms of opera-
tional materials and equipment and have non-
specific readout problems. The qRT-PCR-based 
method detects target miRNAs by PCR, and it ex-
tensively relies on the success of cDNA synthesis, 
which is initiated by priming miRNAs with a short 
adaptor. Failure of the primers to conjugate with the 
miRNAs could result in false negatives. In the case of 
microarray analysis, a probe must hybridize with the 
miRNA in a fixed temperature, even though miR-
NAs vary in their melting temperatures. This intrin-
sic limitation often causes readouts to be false posi-
tives or false negatives.99 Therefore, many research 
groups have extensively investigated ways to build 
efficacious tools for rapid, simple and specific miR-
NA detection as alternatives to the conventional meth-
ods. To date, many new methods have been suggest-
ed, such as nanomaterial-derived methods, non-
PCR-based amplification methods, electrochemical 
methods, etc. The newly developed methods focus 
on simplicity, lower cost, and better sensitivity and 
specificity as the common concepts. Here, we have 
discussed a class of the miRNA detection methods 
by exploiting the photoluminescent characteristics of 
AgNCs. Compared to other methods, the AgNCs-
based methods have many advantages in monitoring 
miRNAs, such as the ease of applicability, the ex-
tremely low cost of materials, a wide range of fluo-
rescence properties, and the feasibility of both on-
and-off signal platforms. Therefore, we suggest that 
by applying DNA/AgNCs sensor methods, miRNAs 
biomarkers and their expression profiles in neurode-
generative diseases could be easily investigated with-
out cost or labor problems.
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